Back to Pulmonology
Pulmonologyv2012Evidence-Based

GAP Index for Idiopathic Pulmonary Fibrosis (IPF) Mortality

Provides 1, 2, and 3-year mortality estimates for IPF patients. The GAP Index uses Gender, Age, and Physiology (FVC and DLCO) to predict mortality risk and guide clinical management decisions.

Clinical Input Parameters

years
Range: 18 — 100 years
percent
Range: 10 — 150 percent
percent
Range: 5 — 150 percent
Clinical Assessment
Awaiting Parameters
gap score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The GAP Index for Idiopathic Pulmonary Fibrosis (IPF) Mortality is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within pulmonology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

GAP Score = Gender points + Age points + FVC points + DLCO points (0-8 total)

Clinical Pearls & Practice Notes

  • Validated in 558 IPF patients from three academic centers in US and Italy
  • Can be used both at presentation and during follow-up throughout disease course
  • Stage I (0-3 points): Monitor every 6 months, may not need immediate transplant listing
  • Stage II (4-5 points): Monitor every 3-6 months, consider transplant evaluation
  • Stage III (6-8 points): Monitor every 3 months, urgent transplant evaluation
  • Higher GAP scores associated with significantly poorer prognosis (p<0.001)
  • DLCO cannot perform = 3 points (most severe category)
  • Antifibrotic therapy may be considered for all stages but especially Stage II-III
  • Should be used in conjunction with clinical judgment and other prognostic factors
  • Validated for use in idiopathic pulmonary fibrosis specifically

Evidence & Literature Citations

  1. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.
  2. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723-8. doi: 10.1378/chest.13-1474.
  3. Paterniti MO, Bi Y, Rekić D, et al. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.

Score Interpretation Ranges

GAP Stage I0 – 3 pts

Low mortality risk

GAP Stage II4 – 5 pts

Intermediate mortality risk

GAP Stage III6 – 8 pts

High mortality risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.